Akèy › Timò Nèwo-endokrin
Etid klinik pou Timò Nèwo-endokrin ap rekrite nan Etazini
40 etid pou Timò Nèwo-endokrin ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Washington, DC11 etid
- Philadelphia, PA11 etid
- Rochester, MN9 etid
- Salt Lake City, UT8 etid
- Houston, TX8 etid
- Columbus, OH8 etid
- St. Louis, MO8 etid
- Cleveland, OH7 etid
- Miami, FL7 etid
- Chicago, IL7 etid
- Cedar Rapids, IA7 etid
- New York City, NY7 etid
- Detroit, MI7 etid
- Lexington, KY7 etid
- Dallas, TX6 etid
- Nashville, TN6 etid
- Omaha, NE6 etid
- Charlottesville, VA6 etid
- Portland, OR6 etid
- Mountain View, CA5 etid
- Milwaukee, WI5 etid
- Jacksonville, FL5 etid
- Tampa, FL5 etid
- Seattle, WA5 etid
- Atlanta, GA5 etid
- San Francisco, CA5 etid
- Los Angeles, CA5 etid
- Boston, MA5 etid
- Grand Rapids, MI5 etid
- Ann Arbor, MI4 etid
- Baltimore, MD4 etid
- Buffalo, NY4 etid
- Durham, NC4 etid
- Baldwin Park, CA4 etid
- Fargo, ND4 etid
- Phoenix, AZ4 etid
- Arlington, VA4 etid
- San Diego, CA3 etid
- New Orleans, LA3 etid
- Hartford, CT3 etid
Pa eta
- Alabama3 etid
- Arizona7 etid
- Colorado4 etid
- Connecticut5 etid
- Florid12 etid
- Georgia6 etid
- Illinois8 etid
- Iowa8 etid
- Kalifòni14 etid
- Kentucky7 etid
- Lwizyàn6 etid
- Maryland13 etid
- Massachusetts7 etid
- Michigan11 etid
- Minnesota11 etid
- Missouri9 etid
- Nebraska6 etid
- New Mexico3 etid
- New York9 etid
- North Carolina5 etid
- North Dakota4 etid
- Ohio14 etid
- Oregon6 etid
- Pennsylvania12 etid
- Tennessee7 etid
- Texas11 etid
- Utah8 etid
- Virginia7 etid
- Washington5 etid
- Wisconsin7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06406465Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Ap rekriteFaz 1/2
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT04086485Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06943755Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Ap rekriteFaz 2
Laj 18 a 72 · Tout sèks · Mizajou Sep 28, 2026 · NCT03412877A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06881992Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Ap rekriteFaz 1
24 Months – 18 Years · Tout sèks · Mizajou Sep 25, 2026 · NCT06441331Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 24, 2026 · NCT05237934EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06263088Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07087054Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07165132Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Aug 25, 2026 · NCT03206060Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT07151391An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07132645A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07129252Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT05263050Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Ap rekriteFaz 1/2
Laj 18 a 99 · Tout sèks · Mizajou Jul 13, 2026 · NCT05000294Integrated Cancer Repository for Cancer Research
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Jun 15, 2026 · NCT06041516Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
Ap rekriteVolontè an sante akeyi
Laj 18 a 85 · Tout sèks · Mizajou Jun 10, 2026 · NCT06788886CapTemY90 for Grade 2/3 NET Liver Metastases
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT04339036A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT03093116Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou May 14, 2026 · NCT05636618SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 28, 2026 · NCT06889493Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Apr 20, 2026 · NCT04074135Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.